Details for Patent: 9,173,857

Which drugs does patent 9,173,857 protect, and when does it expire?

Patent 9,173,857 protects MYDAYIS and is included in one NDA.

Summary for Patent: 9,173,857

Patent landscape, scope, and claims:

Title:	Controlled dose drug delivery system
Abstract:	A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising a pharmaceutically active amphetamine salt covered with an immediate-release coating and a pharmaceutically active amphetamine salt covered with an enteric coating wherein the immediate release coating and the enteric coating provide for multiple pulsed dose delivery of the pharmaceutically active amphetamine salt. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
Inventor(s):	Shojaei; Amir (Phoenixville, PA), Read; Stephanie (Philadelphia, PA), Couch; Richard A. (Bryn Mawr, PA), Hodgkins; Paul (Exton, PA)
Assignee:	Shire LLC (Florence, KY)
Application Number:	14/498,130
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,173,857
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 9,173,857

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	MYDAYIS	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	022063-001	Jun 20, 2017	AB2	RX	Yes	No	9,173,857					TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
Takeda Pharms Usa	MYDAYIS	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	022063-002	Jun 20, 2017	AB2	RX	Yes	No	9,173,857					TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
Takeda Pharms Usa	MYDAYIS	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	022063-003	Jun 20, 2017	AB2	RX	Yes	No	9,173,857					TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
Takeda Pharms Usa	MYDAYIS	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	022063-004	Jun 20, 2017	AB2	RX	Yes	Yes	9,173,857					TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER